Evommune Management
Management criteria checks 2/4
Evommune's CEO is Luis Pena, appointed in Apr 2020, has a tenure of 5.67 years. total yearly compensation is $7.44M, comprised of 7.3% salary and 92.7% bonuses, including company stock and options. directly owns 1.63% of the company’s shares, worth $9.02M. The average tenure of the management team and the board of directors is 3.6 years and 5.4 years respectively.
Key information
Luis Pena
Chief executive officer
US$7.4m
Total compensation
| CEO salary percentage | 7.34% |
| CEO tenure | 5.7yrs |
| CEO ownership | 1.6% |
| Management average tenure | 3.6yrs |
| Board average tenure | 5.4yrs |
Recent management updates
No updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2025 | n/a | n/a | -US$63m |
| Jun 30 2025 | n/a | n/a | -US$66m |
| Mar 31 2025 | n/a | n/a | -US$80m |
| Dec 31 2024 | US$7m | US$546k | -US$68m |
Compensation vs Market: Luis's total compensation ($USD7.44M) is above average for companies of similar size in the US market ($USD2.30M).
Compensation vs Earnings: Insufficient data to compare Luis's compensation with company performance.
CEO
Luis Pena (62 yo)
Mr. Luis C. Pena has been Founder, President, Chief Executive Officer and Director at Evommune Inc. since April 2020. He Co-founded Dermira Inc. in August 2010 and has been its Chief Development Officer si...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 5.7yrs | US$7.44m | 1.63% $ 9.0m | |
| Chief Financial Officer | 3.8yrs | US$1.24m | 0.026% $ 141.5k | |
| Chief Business & Legal Officer | 3.5yrs | US$1.36m | 0.026% $ 143.6k | |
| Co-Founder | no data | no data | 0.83% $ 4.6m | |
| Executive Vice President of Operations | 5.4yrs | no data | 0.13% $ 716.8k | |
| Chief Scientific Officer | 3.2yrs | no data | 0.029% $ 160.8k | |
| Senior Vice President of Technical Operations | 3.5yrs | no data | no data | |
| Senior Vice President of Clinical Development | no data | no data | no data |
Experienced Management: EVMN's management team is considered experienced (3.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 5.7yrs | US$7.44m | 1.63% $ 9.0m | |
| Co-Founder | 5.7yrs | no data | 0.83% $ 4.6m | |
| Independent Director | less than a year | no data | no data | |
| Independent Chairman of the Board | 5.2yrs | US$70.08k | 0% $ 0 | |
| Independent Director | 5.4yrs | no data | 0.013% $ 70.8k | |
| Independent Director | 5.6yrs | US$77.36k | 0.075% $ 416.3k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisors | no data | no data | no data | |
| Independent Director | 4.3yrs | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data |
Experienced Board: EVMN's board of directors are considered experienced (5.4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/26 15:29 |
| End of Day Share Price | 2025/12/24 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Evommune, Inc. is covered by 5 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Prakhar Agrawal | Cantor Fitzgerald & Co. |
| Gavin Clark-Gartner | Evercore ISI |
| Thomas Smith | Leerink Partners LLC |